SALT LAKE CITY, Utah, June 21, 2016 /PRNewswire/ --
In an interview with Stock Radio, Kuhn describes the "enormous" potential for making money in the low price sector, and calls Pulmatrix (NASDAQ: PULM) a "fascinating" opportunity
TheStockRadio.com, which is dedicated to disseminating "real news" from growing companies, announced today that it has released an interview: http://thestockradio.com/konrad-j-kuhn-publisher-at-the-konlin-letter-3047.html with Konrad Kuhn, editor and publisher of the KonLin Letter, one of the nation's top investment newsletters covering small-cap stocks.
In the interview, Kuhn tells how he began trading in the market in his 20s-and because of his rigorous technical analyses, made money right from the start. In 1982, he launched his newsletter. But he really made his mark in 1987 when he correctly predicted that the 1987 market plunge would be a temporary aberration, not a devastating recession.
Most important, he focused on small-cap stocks. "We really, really like the small stock sector," Kuhn explains. "It is rough. It is hard. But you can make an enormous amount of money in the low price stock sector by using technical analysis." Buy a stock at $1 and if it goes up just $1 or $2 more, you've doubled or tripled your money. "The biggest percentage gainers have been in the small cap sector," he says.
In his newsletter, Kuhn gives expert advice on market trends. "We have over 100 indicators that we follow on the market daily," he says.
He also names what he calls the "#1 Stock Pick of the Year."
"We think this is a fascinating company, for more reasons than one," he explains in the Stock Radio interview. "PULM is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease. It is focused on treatments for rare diseases, including cystic fibrosis, with substantial unmet medical needs." Its innovative technology allows virtually any type of drug to be easily carried deep into the lungs to treat those conditions, Kuhn says.
Moreover, he points out, Pulmatrix is partnering with pharmaceutical giant Mylan Labs to co-develop a branded generic version of an already approved inhaled drug for chronic obstructive pulmonary disease (COPD). "The future, on a small little company like this, is enormous," he says. He predicts that once the company's stock rises above $3.50, "we could see a doubling to $8.50 to $9."
About The Stock Radio
TheStockRadio is a small-cap research and investment commentary provider. TheStockRadio.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on TheStockRadio please visit http://thestockradio.com.
TheStockRadio.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. TheStockRadio.com is a Web site wholly owned by Allan James Group. TheStockRadio.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, TheStockRadio.com, for complete risks and disclosures. Contact: firstname.lastname@example.org
This press release contains "forward-looking statements," as defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future.
Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the statements contained in this press release are reasonable, there can be no assurance that such statements will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our most recent annual report for our last fiscal year, our quarterly reports, and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
VP of Operations